Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1682852 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $54.49Day −2.36%Mkt cap $21.6B1Y +66.8%Off 52W high −36.3%Vol (1Y) 69.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,916 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.2% of sh out |
| Days to cover6.1d |
| 13F net flow (QoQ)+3.65% |
| Top-10 13F concentration63.0% |
| Next report (est.)2026-08-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.23B |
| Earnings (TTM)-$3.19B |
| ROE−28.9% |
| Net margin−145.2% |
| ROIC−31.1% |
| Debt / equity0.07× |
| Sales growth 3Y−53.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+84.8% |
| 1Y+66.8% |
| 3Y−53.7% |
| 5Y−84.2% |
| Since incept. (ann.)+15.1% |
Total return through 2026-07-29 · series begins 2018-12-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.7% |
| Ann. volatility (3Y)65.1% |
| Sharpe (1Y)1.03 |
| Sharpe (3Y)−0.08 |
| Max drawdown (1Y)−34.1% |
| Max drawdown (3Y)−86.6% |
| Beta (3Y vs SPY)0.39 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 45.7M | $2.3B | 11.51% | +62.9% |
| BlackRock, Inc. | 29.6M | $1.5B | 7.47% | −8.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 22.9M | $1.2B | 5.76% | new |
| BAILLIE GIFFORD & CO | 20.0M | $1.0B | 5.04% | −2.9% |
| Capital World Investors | 18.7M | $950M | 4.71% | +45.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.6M | $793M | 3.94% | new |
| STATE STREET CORP | 14.9M | $755M | 3.75% | −9.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 9.4M | $478M | 2.38% | +2.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-01 | −$3.40 | — | $389.0M | +260.2% |
| 2025-12-31 | 2026-02-13 | — | — | $678.0M | −29.8% |
| 2025-09-30 | 2025-11-06 | −$0.51 | −1800.0% | $1.02B | −45.4% |
| 2025-06-30 | 2025-08-01 | −$2.13 | — | $142.0M | −41.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-01 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
US 62% · Rest Of World 36% · Europe 3%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
